355 related articles for article (PubMed ID: 25429431)
1. Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.
Terlikowska KM; Witkowska AM; Zujko ME; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2014 Nov; 15(12):21703-22. PubMed ID: 25429431
[TBL] [Abstract][Full Text] [Related]
2. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
3. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
Baghbani F; Moztarzadeh F
Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
5. Curcumin for chemoprevention of colon cancer.
Johnson JJ; Mukhtar H
Cancer Lett; 2007 Oct; 255(2):170-81. PubMed ID: 17448598
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of oxaliplatin in epithelial ovarian cancer.
Fu S; Kavanagh JJ; Hu W; Bast RC
Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
[TBL] [Abstract][Full Text] [Related]
7. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
8. Treatment of platinum-resistant ovarian cancer.
Trimble EL; Wright J; Christian MC
Expert Opin Pharmacother; 2001 Aug; 2(8):1299-306. PubMed ID: 11584998
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies.
Allegra A; Innao V; Russo S; Gerace D; Alonci A; Musolino C
Cancer Invest; 2017 Jan; 35(1):1-22. PubMed ID: 27996308
[TBL] [Abstract][Full Text] [Related]
11. Molecular Targets of Curcumin and Its Therapeutic Potential for Ovarian Cancer.
Mohamadian M; Bahrami A; Moradi Binabaj M; Asgharzadeh F; Ferns GA
Nutr Cancer; 2022; 74(8):2713-2730. PubMed ID: 35266849
[TBL] [Abstract][Full Text] [Related]
12. [Curcumin in chemoprevention of breast cancer].
Terlikowska K; Witkowska A; Terlikowski S
Postepy Hig Med Dosw (Online); 2014 Jan; 68():571-8. PubMed ID: 24864107
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.
Pchejetski D; Alfraidi A; Sacco K; Alshaker H; Muhammad A; Monzon L
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1659-71. PubMed ID: 26560874
[TBL] [Abstract][Full Text] [Related]
14. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
[TBL] [Abstract][Full Text] [Related]
15. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
16. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
18. Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.
Pastò A; Pagotto A; Pilotto G; De Paoli A; De Salvo GL; Baldoni A; Nicoletto MO; Ricci F; Damia G; Bellio C; Indraccolo S; Amadori A
Oncotarget; 2017 Jan; 8(4):6433-6445. PubMed ID: 28031535
[TBL] [Abstract][Full Text] [Related]
19. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
20. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
